Pharmacy Healthcare Solutions Inc. (PHSI) consults with pharmaceutical manufacturers, PBMs, retail pharmacy chains, and software companies on strategic business and marketing issues. Consulting projects across these market segments provide PHSI with the latest information on emerging trends as well as new products and services. Our consultants have extensive retail, mail service and managed care experience to create actionable recommendations for our clients’ challenging business issues.
Signup for free and listen to PHSI Vice President Don Dietz and Director of Business Development Fred Hamlin discuss factors influencing generic pharmaceutical pricing dynamics, impact of generic price changes, and increasing share of top pharmacy chains & effects on generic purchasing leverage.
PHSI Vice President Don Dietz and Director of Business Development Fred Hamlin will be attending AMCP Nexus 2014 in Boston, MA on October 8-10. Contact PHSI to schedule a meeting with Don and Fred during the conference.
The 2015 Summer Edition of the PHSI Newsletter is now available to read here. This issue of the newsletter focuses on the growing trend of telehealth and the effects on telepharmacy. If you would like to receive the newsletter electronically, click here to sign up for our e-Newsletter Mailing List!
On July 13, the Drug Enforcement Administration (DEA) announced the reinstatement of Drug Take-Back Days, with the 10th Take-Back Day scheduled for September 26, 2015 in 48 states; Take-Back Days in Pennsylvania and Delaware will take place on September 12. Visit https://www.deadiversion.usdoj.gov/SEARCH-NTBI/ to locate a collection site near you. Termination and Reinstatement of DEA-Sponsored Take-Back Read More →
On May 20, 2015, Dr. Karen Thacker of the Allegheny County Health Department issued a press release announcing a standing order to allow pharmacists in Allegheny County (Pennsylvania) to dispense intranasal and injectable naloxone without a prescription to at-risk patients and caregivers. This standing order is allowed by Pennsylvania Act 139, which was passed in Read More →
CMS issued a new guidance on biosimilar reimbursement. It sounds simple but now the drug compendia must link the biosimilar with the originator or someone else will meet this marketplace need.